Clinical Significance of National Institutes of Health-Chronic Prostatitis Symptom Index Pain Score in Patients with Benign Prostatic Hyperplasia
Purpose: Many benign prostatic hyperplasia (BPH) patients were accompanied by pelvic pain apart from urinary symptoms. Therefore, we evaluate the treatment outcomes of alpha-blockers via a change of international prostate symptom score (IPSS) according to pain score of the National Institutes of Hea...
Saved in:
Published in | Urogenital tract infection Vol. 10; no. 2; pp. 102 - 107 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
대한요로생식기감염학회
01.10.2015
|
Subjects | |
Online Access | Get full text |
ISSN | 2465-8243 2465-8510 2465-8510 |
DOI | 10.14777/uti.2015.10.2.102 |
Cover
Summary: | Purpose: Many benign prostatic hyperplasia (BPH) patients were accompanied by pelvic pain apart from urinary symptoms. Therefore, we evaluate the treatment outcomes of alpha-blockers via a change of international prostate symptom score (IPSS) according to pain score of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI).Materials and Methods: A total of 356 male patients with BPH from March 2011 to May 2014 were analyzed retrospectively. Prostate specific antigen, prostate volume, IPSS, NIH-CPSI, international index of erectile function (IIEF-5), and uroflowmetry were collected. Patients were categorized according to 2 groups based on the presence and severity of pain and baseline characteristics and treatment outcomes were analyzed.Results: Two hundred twenty-nine patients (64.3%) reported pain/discomfort on NIH-CPSI. Mean IPSS, mean voiding symptoms, mean storage symptoms on IPSS, and mean IIEF-5 showed a significant difference in groups 1A and 1B. Logistic regression analysis showed that NIH-CPSI pain score was a significant predictive factor for severe IPSS (odds ratio, 2.830; 95% confidence interval, 1.307-6.129). After treatment for 3 months, improvement of IPSS, voiding symptoms, storage symptoms, and quality of life was observed in all groups (p=0.001, p<0.001, p=0.026, p<0.001, p<0.001, p<0.001, p<0.001, p<0.001). Group 2B (pain score>5) showed greater improvement of symptoms and statistically significant difference compared with group 2A (pain score ≤5) (p=0.029, p=0.026).Conclusions: We suggest that the presence and severity of pain score are helpful for therapeutic efficacy in patients with BPH. KCI Citation Count: 0 |
---|---|
Bibliography: | G704-SER000001539.2015.10.2.007 |
ISSN: | 2465-8243 2465-8510 2465-8510 |
DOI: | 10.14777/uti.2015.10.2.102 |